- Home
- ODYS vs OPTN Comparison
ODYS vs OPTN Comparison
Compare ODYS & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- OPTN
- Stock Information
- Founded
- ODYS N/A
- OPTN 2010
- Country
- ODYS Israel
- OPTN United States
- Employees
- ODYS N/A
- OPTN N/A
- Industry
- ODYS
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ODYS
- OPTN Health Care
- Exchange
- ODYS NYSE
- OPTN Nasdaq
- Market Cap
- ODYS 86.1M
- OPTN 92.8M
- IPO Year
- ODYS N/A
- OPTN 2017
- Fundamental
- Price
- ODYS $5.36
- OPTN $9.43
- Analyst Decision
- ODYS Strong Buy
- OPTN Hold
- Analyst Count
- ODYS 1
- OPTN 3
- Target Price
- ODYS $10.00
- OPTN $9.00
- AVG Volume (30 Days)
- ODYS 32.2K
- OPTN 25.9K
- Earning Date
- ODYS 03-28-2025
- OPTN 05-20-2025
- Dividend Yield
- ODYS N/A
- OPTN N/A
- EPS Growth
- ODYS N/A
- OPTN N/A
- EPS
- ODYS N/A
- OPTN N/A
- Revenue
- ODYS $3,964,000.00
- OPTN $78,226,000.00
- Revenue This Year
- ODYS N/A
- OPTN $30.49
- Revenue Next Year
- ODYS N/A
- OPTN $13.51
- P/E Ratio
- ODYS N/A
- OPTN N/A
- Revenue Growth
- ODYS 30.70
- OPTN 10.20
- 52 Week Low
- ODYS $5.01
- OPTN $4.82
- 52 Week High
- ODYS $10.80
- OPTN $20.03
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- OPTN 77.60
- Support Level
- ODYS N/A
- OPTN $9.37
- Resistance Level
- ODYS N/A
- OPTN $9.45
- Average True Range (ATR)
- ODYS 0.00
- OPTN 0.07
- MACD
- ODYS 0.00
- OPTN -0.06
- Stochastic Oscillator
- ODYS 0.00
- OPTN 86.21
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.